Answers are grounded in this paper and cite their sources.
Innovative biosensor detects multiplexed lung cancer biomarkers from extracellular vesicles, suggesting a new diagnostic tool.
We introduce the EV-Disrupt and Detect System (EDDS), an innovative, portable biosensor utilizing electrochemical impedance spectroscopy (EIS) for the swift, low-volume, and economical assessment of extracellular vesicle (EVs)-related lung cancer biomarkers. The EDDS combines electric field-induced EVs disruption with the simultaneous detection of 4 critical biomarkers: TSG101, EGFR, GPC1, and GM2AP, directly from serum. EVs disruption occurred within 30 seconds utilizing a 50 mV, 1 kHz square wave, with disruption efficiency validated by nanoparticle tracking analysis (93.9%) and Western blotting to ensure protein integrity. Post-disruption, the released cargo was quantified by electrochemical impedance spectroscopy (EIS) across 4 specialized screen-printed electrodes (SPEs), with results corroborated by enzyme-linked immunosorbent test (ELISA). The electric field parameters (voltage, frequency, and duration) were optimized with 150 μL of serum, yielding a 0.218-2.809-fold enhancement in detectable biomarker concentrations. The EDDS markedly decreases processing time, cost, and technological complexity by obviating the necessity for traditional EVs isolation techniques such as ultracentrifugation or chromatography. This integrated platform facilitates direct EVs disruption and multiplexed biomarker identification within a singular workflow, providing a robust instrument for minimally invasive cancer diagnostics and advancing broader clinical applications in liquid biopsy.
No takes yet. Share an insight, caveat, or question.
Praween et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: